Пређи на садржај

Melfalan

С Википедије, слободне енциклопедије
Melfalan
Klinički podaci
Prodajno imeAlkeran, L-PAM, L-Phenylalanine mustard, L-Sarcolysin
DrugsMonografija
Način primeneOralno
Farmakokinetičkipodaci
Poluvreme eliminacije1,5 h
Identifikatori
CAS broj148-82-3ДаY
ATC kodL01AA03(WHO)
PubChemCID4053
DrugBankDB01042ДаY
ChemSpider405297ДаY
ChEBICHEBI:28876ДаY
ChEMBLCHEMBL852ДаY
Hemijski podaci
FormulaC13H18Cl2N2O2
Molarna masa305,200
  • N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
  • InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1ДаY
  • Key:SGDBTWWWUNNDEQ-LBPRGKRZSA-NДаY
Fizički podaci
Tačka topljenja1.825 °C (3.317 °F)

Melfalanjeorgansko jedinjenje,koje sadrži 13atomaugljenikai imamolekulsku masuod 305,200Da.[1][2][3][4][5]

Osobina Vrednost
Broj akceptora vodonika 4
Broj donora vodonika 2
Broj rotacionih veza 8
Particioni koeficijent[6](ALogP) -0,1
Rastvorljivost[7](logS,log(mol/L)) -4,0
Polarna površina[8](PSA,Å2) 66,6
  1. ^Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N: Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. Chem Res Toxicol. 2008 Apr;21(4):787-95. Epub 2008 Feb 14.PMID18324787
  2. ^Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP: Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15.PMID16781199
  3. ^Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer. 1993 Oct;68(4):732-7.PMID8398701
  4. ^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709Слободан приступ.PMID21059682.doi:10.1093/nar/gkq1126.
  5. ^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889Слободан приступ.PMID18048412.doi:10.1093/nar/gkm958.
  6. ^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.
  7. ^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID11749573.doi:10.1021/ci000392t.
  8. ^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID11020286.doi:10.1021/jm000942e.


Molimo Vas, obratite pažnju navažno upozorenje
u vezi sa temama izoblasti medicine (zdravlja).